Comprehensive Management of Heart Failure with Reduced Ejection Fraction

First-Line Medications

• The European Society of Cardiology recommends a comprehensive treatment regimen including a beta-blocker, ARNI (sacubitril/valsartan), MRA (mineralocorticoid receptor antagonist), SGLT2 inhibitor (dapagliflozin), and diuretics as needed for congestion, to significantly reduce mortality and hospitalization in patients with HFrEF 1, 2, 3
• Beta-blockers are recommended for all patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death, according to the European Heart Journal 1, 4
• The American College of Cardiology recommends that beta-blockers should be initiated at low doses and gradually titrated to target doses as tolerated in patients with HFrEF 4, 5
• The European Society of Cardiology states that beta-blockers are contraindicated in patients with severe bradycardia or high-degree heart block 5

Additional Therapies

• The European Heart Journal recommends sacubitril/valsartan as a replacement for ACE inhibitors or ARBs in patients with HFrEF who remain symptomatic despite optimal treatment, providing superior reduction in HF hospitalization and death 1, 6
• The European Society of Cardiology recommends MRAs for patients with HFrEF who remain symptomatic despite treatment with beta-blockers and ACE inhibitors/ARBs/ARNIs, with options including spironolactone or eplerenone 1, 4
• The European Heart Journal strongly recommends dapagliflozin for patients with HFrEF to reduce the risk of HF hospitalization and cardiovascular mortality, with beneficial effects independent of diabetes status 2

Device Therapies

• The European Heart Journal recommends ICDs for patients with symptomatic HF (NYHA Class II-III), LVEF ≤35% despite ≥3 months of optimal medical therapy, and not within 40 days of myocardial infarction 1, 2
• The European Society of Cardiology recommends CRT for symptomatic patients with HF in sinus rhythm with QRS duration ≥150 msec and LBBB QRS morphology with LVEF ≤35% despite optimal medical therapy 1

Implementation Strategy

• The Journal of the American College of Cardiology recommends starting with low doses of multiple medications simultaneously rather than waiting to reach target doses of one medication before starting another, with gradual increase to target doses over 6-12 weeks 7
• The European Heart Journal recommends regular assessment of symptoms, functional capacity, blood pressure, renal function, electrolytes, heart rate, and rhythm in patients with HFrEF 1, 4, 5

Common Pitfalls to Avoid

• The European Journal of Heart Failure warns against underutilization of guideline-directed medical therapy, inadequate dose titration, and inappropriate discontinuation of medications in patients with HFrEF 4, 5
• The European Heart Journal advises avoiding NSAIDs due to potential worsening of renal function and counteraction of beneficial effects of GDMT 4, 5
• The European Society of Cardiology recommends actively managing comorbidities such as iron deficiency, hypertension, and atrial fibrillation in patients with HFrEF 2